Related Experiment Video

Updated: Jul 6, 2026

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

[Antimicrobial and antimycotic therapy of intra-abdominal infections]

P Kujath1, M Hoffmann, A Rodloff

  • 1Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. peter.kujath@chirurgie.uni-luebeck.de

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|March 13, 2008
PubMed

Insights

Prompt antibiotic therapy is crucial for intra-abdominal infections (IAI). Treatment selection depends on patient risk factors and pathogen profiles, guiding empirical therapy and specific interventions for peritonitis and mycoses.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Critical Care Medicine

Context:

  • Intra-abdominal infections (IAI) necessitate prompt antimicrobial chemotherapy.
  • Empirical antibiotic therapy selection is based on predicted bacterial spectrum.
  • Clinical trials often focus on non-inferiority, complicating general recommendations.

Purpose:

  • To outline the principles of antimicrobial chemotherapy for intra-abdominal infections.
  • To emphasize the importance of risk-stratified and pathogen-guided treatment.
  • To address specific considerations for postoperative peritonitis and fungal infections.

Summary:

  • Initiation of antibiotic therapy must be immediate upon IAI diagnosis.
  • Treatment strategies for postoperative peritonitis should incorporate patient risk profiles, including prior antibiotic exposure and local epidemiology of resistant pathogens.
  • Invasive peritoneal mycoses are infrequent but require targeted therapy based on microbiological analysis.

Impact:

  • Provides a framework for optimizing antimicrobial selection in complex intra-abdominal infections.
  • Highlights the need for individualized treatment plans based on risk assessment and microbiological data.
  • Informs clinical decision-making for healthcare providers managing IAI and associated complications.

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...